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GH3 cellsPituitary tumors belong to the group of most common neoplasms of the sellar region. Iodothyronine deiodinase
types 1 (DIO1) and 2 (DIO2) are enzymes contributing to the levels of locally synthesized T3, a hormone regulating
key physiological processes in the pituitary, including its development, cellular proliferation, and hormone secre-
tion. Previous studies revealed that the expression of deiodinases in pituitary tumors is variable and, moreover,
there is no correlation between mRNA and protein products of the particular gene, suggesting the potential role
of posttranscriptional regulatory mechanisms. In this work we hypothesized that one of such mechanisms could
be the alternative splicing. Therefore, we analyzed expression and sequences of DIO1 and DIO2 splicing variants
in 30 pituitary adenomas and 9 non-tumorous pituitary samples. DIO2mRNA was expressed as only two mRNA
isoforms. In contrast, nine splice variants ofDIO1were identiﬁed. Among them,ﬁvewere devoid of exon 3. In silico
sequence analysis of DIO1 revealed multiple putative binding sites for splicing factor SF2/ASF, of which the
top-ranked sites were located in exon 3. Silencing of SF2/ASF in pituitary tumor GH3 cells resulted in change of
ratio between DIO1 isoforms with or without exon 3, favoring the expression of variants without exon 3. The
expression of SF2/ASFmRNA in pituitary tumors was increasedwhen comparedwith non-neoplastic control sam-
ples. In conclusion, we provide a newmechanism of posttranscriptional regulation of DIO1 and show deregulation
of DIO1 expression in pituitary adenoma, possibly resulting from disturbed expression of SF2/ASF.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Pituitary adenomas belong to the group of the most common
tumors of the sellar region and account for 10–25% of all intracranial
tumors [1,2]. Despite the rare malignancy, pituitary tumors cause high
morbidity due to severe endocrine effects and difﬁculties in surgical
access. Molecular basis of pituitary oncogenesis is largely unknown;
mutations in genes coding for tumor suppressors and oncogenes areype 1; DIO2, iodothyronine
, 3,5,3′-triiodothyronine; rT3,
factor; NFPA, nonfunctioning
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rights reserved.not frequently observed in pituitary tumors [1]. It is postulated there-
fore that the alterations in key signaling pathways leading to enhanced
proliferation are the most possible mechanisms that underlie pituitary
tumorigenesis. Thyroid hormone signaling is one of the key elements
regulating the physiology of the pituitary gland. In pituitary cells, thy-
roxine (T4), the prohormone secreted by the thyroid gland, undergoes
conversion to 3,3′,5-triiodothyronine (T3) which is a ligand for speciﬁc
transcription factors, called the thyroid hormone receptors (TRs). TRs
regulate expression of target genes (e.g. coding for hormones secreted
by the gland: TSH, PRL, and GH) in a T3-dependent manner [3–5]. By
means of this regulation, thyroid hormones inﬂuence development
and proliferation of pituitary cells [6,7]. The signaling pathway of thy-
roid hormone is often disturbed in different types of neoplasia [8–10].
One of the key-limiting steps in T3-dependent regulation of gene
expression is cellular availability of T3, dependent on the T4- to T3 con-
versionwhich is catalyzed by selenoenzymes, iodothyronine deiodinase
types 1 (DIO1) and 2 (DIO2) [11].
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pre-mRNA regions (introns) which do not code for a mature transcript
and joining of residual coding regions (exons) to produce functional
mRNA [12]. This is a widespread process, inﬂuencing the expression
of more than 90% of all human protein-coding genes [13]. As a result
of alternative splicing, multiple mRNAs can be produced from a single
gene. During alternative splicing, speciﬁc splice sites are selected due
to coordinated actions of large number of proteins, including splicing
factors called serine–arginine rich proteins (SR proteins) which bind
to speciﬁc regulatory sequences called ESE or ISE (exonic splicing
enhancers or intronic splicing enhancers, respectively) [14]. Moreover,
splicing factors can act as proto-oncogenes, capable of inducing tumoral
transformation as it was shown for splicing factor SF2/ASF [15–18]. Dis-
turbances of alternative splicing can lead to synthesis of improperly
spliced mRNA isoforms which, if translated, may produce aberrant pro-
teins. This is particularly often observed in different types of neoplasia
[19]. Causes of disturbed alternative splicing includemutations in splice
sites of primary transcripts and improper expression of splicing factors
that regulate this process. We have previously shown that alternative
splicing of type 1 iodothyronine deiodinase (DIO1) is disturbed in
renal cancer and that these disturbances are associated with aberrant
expression of splicing factors [20,21]. That study also revealed that dis-
turbed alternative splicing ofDIO1 transcript results in synthesis of tran-
script variants that lack key regions coding for catalytically active site of
DIO1.
At least three studies addressed the expression of iodothyronine
deiodinases in pituitary tumors [22–24]. Itagaki et al. detected no or
variable activities of DIO2 in different types of adenomas [22]. Tannahill
et al. found that compared with non-neoplastic pituitaries, the expres-
sion of DIO2 was increased in pituitary tumors except for a rare TSH-
secreting tumor in which signiﬁcant reduction of mRNA expression
was observed [24]. In the study of Baur et al., the expression of DIO2
was highly variable [23]. The results regarding DIO1 were conﬂicting:
in one study DIO1 activity was absent from most of pituitary adenoma
samples [24], while the study by Baur et al. [23] proved that the gene
is expressed in adenoma tissue.
In the current study we hypothesized that the alternative splicing
of DIO1 and DIO2 is disturbed in pituitary tumors. Therefore we aimed
to identify and analyze the potential alternatively spliced isoforms of
deiodinases' mRNA in pituitary adenomas and in non-neoplastic pitu-
itary samples. We also aimed to identify potential causes of altered
splicing, such as mutations or polymorphisms in splicing regulatory
sequences and changes in expression of splicing factor predicted to
bind in ESE in deiodinase coding gene.
2. Material and methods
2.1. Ethics statement
All human tissue samples were obtained with approval of the Bio-
ethics Committee of the Institute of Psychiatry and Neurology in
Warsaw. Written informed consent was given by all patients enrolled
in the study.
2.2. Patients and samples
Thirty pituitary adenoma specimens were obtained at the time of
transsphenoidal surgery. A portion of tissue was ﬂash frozen and stored
at−70 °C. The remaining tissue samples were ﬁxed in 4% paraformalde-
hyde andembedded inparafﬁn for routine histological and immunohisto-
chemical evaluation, and in 2.5% glutaraldehyde and1%osmium tetroxide
for electron microscopy. The classiﬁcation of pituitary adenomas was
based on endocrine proﬁles, immunohistochemical staining for anterior
pituitary hormones and ultrastructural ﬁndings according to WHO
criteria [25]. Patient clinical data, histological and immunohistochemical
proﬁles and molecular ﬁndings are summarized in Table 1. All pituitarytumors were macroadenomas, with most cases of nonfunctioning pitui-
tary adenomas (NFPAs), including silent gonadotroph adenoma (n=
20), null cell adenoma (n=3), silent prolactinoma (n=1) and subtype
3 adenoma (n=2). Moreover, there were also GH-secreting tumors
(n=3) with clinical presentation of acromegaly and ACTH-secreting
adenoma (n=1) with Cushing disease. Nine normal, non-neoplastic
human pituitary glands were obtained from autopsy cases with no evi-
dence of endocrine abnormalities. The postmortem studies were
performed within 24 h of the time of death.
Poly A+ RNA isolated from normal human pituitary glands pooled
from 88 male/female Caucasians (ages: 16–68; cause of death: sudden
death) was purchased from Clontech (Mountain View, CA, USA).
cDNA from ﬁve papillary thyroid carcinoma and matched
non-tumorous thyroid tissue samples was a kind gift of Dr. Krystian
Jazdzewski.2.3. Cell culture and siRNA transfections
Rat pituitary tumor cell line GH3 (ATCC no. CCL-82.1) and human
hepatocarcinoma cell line HepG2 (ATCC no. HB-8065) were cultured
according to ATCC recommendations. Since GH3 cells grow as loosely
adherent cells with ﬂoating clusters, the standard transfection proce-
dure for adherent cultures can result in detachment of cells and bias
the results due to uneven transfection. To avoid this, the protocol
for reverse transfection was used. Cells were added directly to the
Lipofectamine–siRNA complexes and subsequently seeded, allowing
for transfection to occur during the process of cell attachment to the
well. For RNA isolations and subsequent RT-PCR experiments the cells
were transfected in 12-well plates. Brieﬂy, in two separate Eppendorf
tubes two mixtures were prepared: 1) 2.5 μl Lipofectamine 2000 with
247.5 μl Opti-MEM (Life Technologies, Carlsbad, CA, USA), and 2) 24 μl
siRNA (150 pmol) (Life Technologies, Carlsbad, CA, USA) with 226 μl
Opti-MEM. After 10 minute incubation in room temperature the mix-
tures were combined and incubated for additional 15 min. Then, the
Lipofectamine–siRNA mix was added to a plate well and 2×105 cells
suspended in 1000 μl of full growth medium without antibiotics were
added. The transfection was performed for 48 h and RNA was isolated.
For protein isolations and subsequent Western-blot analysis, the trans-
fectionswere performed in 25 cm2 ﬂasks for 72 h, using 1.32×106 cells
and appropriately increased amounts of reagents.2.4. RNA isolation and reverse transcription
RNA was isolated from tissue samples using AllPrep DNA/RNA/
Protein Mini Kit (Qiagen, Hilden, Germany) and from cultured cells
using Universal RNA Puriﬁcation Kit (EURx, Gdansk, Poland) according
to the manufacturer's instructions. The quantity and quality of RNA
were conﬁrmed using spectrophotometry and gel electrophoresis.
Reverse transcription was performed as described previously using
100 ng of RNA per reaction [20].2.5. Real-time PCR
Real-time PCR analysis of SF2/ASFwas performed as described previ-
ously [21]. The expression of DIO1 and DIO2 mRNA was analyzed using
TaqMan probes Hs01551166_m1 and Hs00255341_m1, respectively
(Applied Biosystems, Foster City, CA, USA). Results were normalized to
expression of ACTB housekeeping gene. The stability of expression of
ACTB was validated and conﬁrmed in initial pre-analysis of 32 pituitary
control and tumor samples by comparison with 18sRNA and GAPDH
expression. Sequences of primers are shown in Table 2. The expression
of SF2/ASF inGH3 cellswas normalized to cyclophilin A as described pre-
viously [26].
Table 1
Clinical, immunohistochemical and molecular (SNPs, identiﬁed mutation in DIO1 gene, and identiﬁed DIO1 splice variants) characteristics of tissue samples used in the study. NFPA: non-functioning pituitary adenoma; NA: not analyzed; ND:
not detected.
Sample
no.
Diagnosis Immunohistochemistry Tumor size Sample code Age Sex 15710C-A
(rs2235544)
15841C-T
(rs11206244)
DIO1 splice
variants
DIO1 mutations
1. NFPA, silent gonadotroph adenoma FSH (+/−), LH (+/−) Macro, invasive 8p 75 M C/A C/T v1 ND
2. NFPA, silent gonadotroph adenoma FSH (+), LH (+) Macro 9p 68 F C/C C/C v3 ND
3. NFPA, silent gonadotroph adenoma FSH (+), LH (+), αSU (+) Macro 20p 63 F A/A T/T v1, v4 ND
4. NFPA, silent gonadotroph adenoma FSH (+), LH (+), αSU (+) Macro 24p 57 M A/A T/T v4, FJ002245 ND
5. NFPA, silent gonadotroph adenoma FSH (+), LH (+/−) Macro 25p 64 F C/A C/T ND ND
6. NFPA, silent gonadotroph adenoma FSH (+), LH (+) Macro
invasive, recurrent
5_09 35 F C/A C/C ND ND
7 NFPA, silent gonadotroph adenoma FSH (+), LH (+) Macro 9_09 79 M A/A C/T v1 C62T,
heterozygotic
8 NFPA, silent gonadotroph adenoma FSH (+) Macro 10_09 54 F A/A C/T v1 ND
9 NFPA, silent gonadotroph adenoma LH (+/−) Macro, recurrent 15_09 63 M C/A C/C NEW JK990800 ND
10 NFPA, silent gonadotroph adenoma FSH (+), LH (+/−) Macro 16_09 49 M C/A C/C v1, v4 ND
11 NFPA, silent gonadotroph adenoma FSH (+), αSU (+) Macro 14_09 71 F A/A T/T v4 ND
12 NFPA, silent gonadotroph adenoma FSH (+) Macro 1p 67 M A/A C/T NEW JK990798 ND
13 NFPA, silent gonadotroph adenoma LH (+/−) Macro 26p 44 F C/C C/C NEW JK990801 ND
14 NFPA, null cell adenoma All negative Macro 5p 79 M A/A T/T ND ND
15 NFPA, silent gonadotroph adenoma FSH (+/−), LH (+) Macro 7p 64 M C/A C/T v1 ND
16 NFPA, silent gonadotroph adenoma FSH (+), LH (+) Macro 14p 69 M C/C C/C NEW JK990798 ND
17 NFPA, silent gonadotroph adenoma FSH (+/−), LH (+) Macro 15p 72 F C/A C/T v1, NEW JK990798 ND
18 NFPA, silent gonadotroph adenoma FSH (+), LH (+), αSU (+) Macro 19p 53 M C/A C/T v4, FJ002245 ND
19 NFPA, silent gonadotroph adenoma FSH (+/−), LH (+/−), αSU (+/−) Macro 8_08 64 M C/C C/C v4, NEW JK990798 ND
20 NFPA, silent gonadotroph adenoma FSH (+), αSU (+/−) Macro 2_09 47 F C/A C/T v1 ND
21 NFPA, silent gonadotroph adenoma LH (+), αSU (+) Macro 11_09 49 M C/C C/C ND ND
22 NFPA, null cell adenoma All negative Macro, recurrent 12_09 57 F C/A C/T v2 ND
23 Acromegaly, plurihormonal (densely granulated
somatotroph/gonadotroph cell adenoma)
GH (+), LH (+), FSH (+/−) Macro, invasive 17_09 69 F C/A C/T FJ002244 ND
24 Acromegaly, mixed densely granulated
somatotroph/lactotroph cell adenoma
GH (+), PRL (+) Macro 2p 42 F C/A C/T ND ND
25 Acromegaly, mixed densely granulated
somatotroph/lactotroph cell adenoma
GH (+), PRL (+) Macro, invasive 16p 63 M C/C C/C v1 ND
26 Cushing's disease, sparsely granulated
corticotroph adenoma
ACTH (+) Macro 7_09 33 M C/A C/T v1 ND
27 NFPA, null cell adenoma All negative Macro 1_09 60 M C/C C/C v1 ND
28 NFPA, silent prolactinoma PRL (+) Macro 18p 50 M C/C C/C ND ND
29 NFPA, silent subtype 3 adenoma PRL (+). TSH (+), αSU (+/−) Macro 17p 55 F A/A T/T ND ND
30 NFPA, silent subtype 3 adenoma GH (+), PRL (+) Macro,
recurrent
8_09 41 F C/C C/C ND ND
Non-neoplastic pituitaries:
31 Brainstem tumor 16200 18 M C/A C/T ND NA
32 Aortic valve stenosis 16216 59 F C/A C/T ND NA
33 Endocarditis 16281 60 M C/A C/T ND NA
34 Infective endocarditis 16284 17 F A/A T/T ND NA
35 Cystic ﬁbrosis 16331 17 M C/C C/C ND NA
36 Myocardial infarction after heart transplantation CH183/12 64 M C/A C/T ND NA
37 Aortic valve stenosis 16520 18 M A/A T/T ND NA
38 Diabetes, myocardial infarction CH174/12 87 F C/A C/T ND NA
39 Aortic valve stenosis, 16717 62 F C/A C/T ND NA
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Table 2
Primers used in real-time PCR.
Target transcript and organism Primer sequence, F: forward, R-reverse Ref.
SF2/ASF F: TTAGATCTCATGAGGGAGAAA [21]
(Homo sapiens, Rattus norvegicus) R: GAGAATAGCGTGGTGATCCT
ACTB F: CGGCATCGTCACCAACTG [29]
(Homo sapiens) R: GCTGGGGTGTTGAAGGTCTC
Cyclophilin A F: TTTTCGCCGCTTGCTGCAGAC [26]
(Rattus norvegicus) R: CACCCTGGCACATGAATCCTGGA
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Ampliﬁcation of splice variants was performed in two-step PCR as
described previously for DIO1 [20] with minor modiﬁcations. The ﬁrst
reaction was performed using 5 times diluted cDNA, Perpetual OptiTaq
DNA Polymerase containing Pfu polymerase (EURx, Gdansk, Poland),
primers D1prom-U (5′-AGCTTACTCTGGCTTTGC-3′) and D1V1V2L
(5′-GTGCCTGTAGAGTGCAACTG-3′), and the following protocol: initial
denaturation at 95 °C for 10 min, followed by 5 cycles (95 °C for 20 s,
62 °C for 20 s, and 72 °C for 1 min; the annealing temperature was
decreased by 0.58 °C in each cycle), then 40 cycles (95 °C for 20 s,
57 °C for 20 s, and 72 °C for 1 min), and ﬁnal elongation at 61 °C for
30 min. PCR products were processed with FastAP™ Thermosensitive
Alkaline Phosphatase and Exonuclease I (Fermentas, Vilnius, Lithuania),
diluted 10 times and served as a template in the second round of
PCR, with primers D1prom-U and D13UTR-L (5′-GATTCAGCTAGGG
ACACAG-3′) and the following protocol: initial denaturation at 95 °C
for 10 min, followed by 45 cycles (95 °C for 20 s, 55 °C for 20 s, and
72 °C for 1 min), and ﬁnal elongation at 61 °C for 30 min.
Ampliﬁcation of DIO2 variants was performed analogically to DIO1.
The ﬁrst reaction was performed using primers Dio2-up1 (5′-TTGCA
CCACAGACAGATAGC-3′) and Dio2-lo1 (5′-TTACTTACTCAGCCCAAT
GC-3′), and the second reaction was performed using primers Dio2-
up2 (5′-CTGGGGAAGGGAGAGAGTG-3′) and Dio2-lo2 (5′ TTTCAGTAA
GCCAATAGG-3′). The protocol was as follows. First PCR: initial
denaturation at 95 °C for 10 min, followed by 5 cycles (95 °C for 20 s,
60 °C for 20 s, and 72 °C for 1 min; the annealing temperature was
decreased by 0.58 °C in each cycle), then 40 cycles (95 °C for 20 s,
57 °C for 20 s, and 72 °C for 1 min), and ﬁnal elongation at 61 °C for
30 min. Second PCR: initial denaturation at 95 °C for 10 min, followed
by 40 cycles (95 °C for 20 s, 55 °C for 20 s, and 72 °C for 1 min), and
ﬁnal elongation at 61 °C for 30 min.
PCR products were processed with FastAP™ Thermosensitive
Alkaline Phosphatase and Exonuclease I (Fermentas, Vilnius, Lithuania),
cloned into pGEMT-Easy vector (Promega, Madison, WI), and trans-
formed into JM109 Competent cells. Subsequent colony PCR was
performed as described previously [21]. Isolation of plasmids was
performed using PlasmidMini kit (A&ABiotechnology, Gdynia, Poland).
Cloned splicing variantswere analyzed in a commercial sequencing ser-
vice (Genomed, Warsaw, Poland).2.7. Analysis of DIO1 and DIO2 splicing in GH3 cells
The obtained cDNA was diluted 5-times and served as a template
in a PCR reaction using primers for DIO1 (Ratex1ex4-F: 5′-GACAGA
AGTGCAACGTCTGG-3′ and Ratex1ex4-R: 5′-TAGAACTGAGGCATGTG
TCC-3) and DIO2 (rDio2ex1ex2-F2: 5′-ATCTCTGCAGTCTCATAG-3′
and rDio2ex1ex2-R: 5′-ACTCTTCCACCAACTGGC-3′) under the follow-
ing conditions: 95 °C for 10 min, followed by 40 cycles (95 °C for
30 s, 57 °C for 1 min, and 72 °C for 30 s), ﬁnal elongation 72 °C for
10 min. PCR products were analyzed on 1.5% agarose gel and scanned
using Gene Tools (Syngene, Cambridge, UK).2.8. Pit1 i POMC analysis
To detect possible contamination of adenoma specimens with
non-tumorous tissue we performed RT-PCR analysis of Pit-1 (primers
Pit-1F: 5′-CATTTACTTCGGCTGATA-3′, Pit-1R: 5′-AGGTTGATGGCTGG
TTTC-3′) and POMC (primers: POMC-F: 5′-AGGACCTCACCACGGA
AAG-3′ and POMC-R: 5′-CATGGAGTAGGAGCGCTTG-3′) as described
previously [27,28].
2.9. Protein isolation and Western-blot analysis
Protein isolation was performed using RIPA buffer as described pre-
viously [29]. ForWestern blotting, 30 μg of protein extractwas resolved
by 10% SDS-PAGE. After electrophoresis the proteins were transferred
onto nitrocellulose membranes that were subsequently blocked over-
night at 8 °C in 5% non-fat milk in TBS-T buffer (10 mM Tris–HCl,
150 mM NaCl, 0.1% Tween-20; pH 7.6). The membranes were washed
three times in TBS-T for 10 min at RT, and incubated for 2.5 h at RT
with anti-SF2/ASF antibody (cat. no.: 32-4500, Invitrogen, Carlsbad,
CA) diluted 1:1000 in TBS-T buffer. After washing 3 times for 10 min
with TBS-T, themembraneswere incubated for 1 h at RTwith horserad-
ish peroxidase-conjugated goat anti-mouse secondary antibody
(1:10,000, Dako, Glostrup, Denmark), and washed 3 times for 10 min
with TBS-T. Detection of β-actin and generation of chemiluminescence
signal were performed as described previously [21].
2.10. Bioinformatic analysis
The sequences of identiﬁed splice variants were compared
with GenBank reference sequences (Dio1: NC_000001.9, region
54132449–54149347, DIO2: NC_000014.8, region 80663869–
80678525) using BLAST. Prediction of splicing factor binding motifs
in DIO1 mRNA sequence was performed using SFmap [30].
2.11. Statistical analysis
Statistical analysis was performed using GraphPad Prism 5. The nor-
mality of data distribution was checked with D'Agostino & Pearson
omnibus test. The data were analyzed using t-test. pb0.05 was consid-
ered statistically signiﬁcant.
3. Results
3.1. Identiﬁcation of DIO1 and DIO2 mRNA isoforms in pituitary samples
DIO1 and DIO2 proteins are products of translation of, respectively,
DIO1 splice variant 1 (GenBank Acc. no. NM_000792.4) and DIO2 splice
variants 1 and 2 (NM_013989.3 and NM_000793.4, respectively). The
two DIO2 splice variants differ only in their 5′ untranslated regions
(UTRs). However, apart from these three main splice variants, several
additional transcripts are known, including DIO1 splice variants previ-
ously described in our study [20].
To amplify and identify the maximum number of DIO1 and DIO2
splice variants we performed two-step PCR using primers shown in
Material and methods. In control samples, no DIO1 splice variants
were found. In contrast, in tumor samplesDIO1 expressionwas variable,
including 11 samples inwhichno PCRproductswere detected aswell as
19 samples in which different PCR products (ranging from ~400 bp to
900 bp) were found (Fig. 1). Electrophoresis of PCR-ampliﬁed DIO2
splice variants revealed two main (~1550 bp and ~1250 bp) and addi-
tional smaller and weaker bands (Fig. 2).
Cloning and sequencing of the ampliﬁed splice variants conﬁrmed the
presence of all reference transcripts ofDIO1 (variants 1, 2, 3, and 4), andof
DIO2 (variants 1 and 2) known from GenBank database. In addition, we
found two DIO1 splice variants (GenBank Acc. numbers FJ002244 and
FJ002245) which were identiﬁed in our previous study performed on
Fig. 1. Alternative splicing and expression of DIO1. A. Representative electrophoretic gels showing expression of DIO1 splice variants in tumors (T) and non-tumorous (C) pituitary
samples. Only ﬁve representative samples out of 30 analyzed pituitary adenoma and of nine control samples are shown. B. Graphical representation of DIO1 splice variants cloned in
the study named with their GenBank accession numbers. The exons are shown as black boxes. Numbers above or below exons refer to nucleotide positions in DIO1 gene
(NC_000001.9, region 54132449…54149347). Catalytically active DIO1 is translated from variant 1. Below the last cloned variant electrophoretic analysis of DIO1 splicing variants
is shown. Numbers above gel refer to numbering of the nine splice variants shown on the cartoon. C. Analysis of exon boundaries in the new DIO1 splice variants, cloned for the ﬁrst
time in this study. The diagram shows sequencing chromatograms of DIO1 splice variants and the sequences of speciﬁc regions of DIO1 gene. The positions of exons and introns are
shown with arrows. The bolded nucleotides follow the consensus of splice sites: GT/AG (5′ splice site: MAG|GTRAGT and 3′ splice site: CAG|G, where M is A or C and R is A or G;
vertical line represents exon/intron boundary). D. Validation of DIO1 mRNA expression in HepG2 cells (n=1) and ﬁve matched pairs of papillary thyroid carcinoma (PTC-T, n=5)
and control thyroid samples (PTC-N, n=5).
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(Fig. 1). Themost abundantwere variant 1 (found in samples 1, 3, 7, 8, 10,
15, 17, 20, 25, 26, and 27), variant 4 (found in samples 3, 4, 10, 11, 18, and
19), and the new splice variant consisting of exons 1 and 4 (numbered 9
in Fig. 1; found in samples 12, 16, 19, and 17). The sequence of all these
splice variants followed the pattern of canonical splice sites (GT/AG)
(Fig. 1).
The splice variants of DIO2 were detectable in both tumor and
non-neoplastic pituitary samples (Fig. 2). Alignment with DIO2 gene
reference sequence revealed that the two major bands represented
splicing variants 1 and 2 (Fig. 2). Sequence analysis of all residual cloned
PCR products revealed that they could not result from the canonical
splice site usage and possibly resulted from the known mechanism of
reverse transcriptase template switching [31,32]. Therefore, they were
discarded from further analysis.3.2. The expression of DIO1 and DIO2 in pituitary samples
To analyze the expression of deiodinases in pituitary samples
we performed real-time PCR using Taqman probes detecting tran-
scripts of DIO1 (variant 1: NM_000792, variant 2: NM_213593, and
variant FJ002244) and DIO2 (variant 1: NM_013989 and variant 2:
NM_000793) in 28 tumor and nine non-neoplastic pituitary samples
that were available for analysis. Additionally, the expression of DIO1
and DIO2 was analyzed in human papillary thyroid carcinoma (PTC)
and control tissue adjacent to PTC, not inﬁltrated with cancer. Since
both deiodinases are expressed in the thyroid [33,34], this material
served as a positive control for the reaction efﬁciency. We also used
HepG2 cell line as a positive control for DIO1 expression [35]. DIO2
expression was statistically signiﬁcantly (pb0.01) decreased in growth-
hormone secreting adenomas when compared with non-tumorous
Fig. 2. Alternative splicing and expression of DIO2. A. Representative electrophoretic gels showing expression of DIO2 splice variants in tumors (T) and non-tumorous (C) pituitary
samples. Only ﬁve representative samples out of 30 analyzed pituitary adenoma samples and of nine control samples are shown. B. Left panel: graphical representation of DIO2
splice variants cloned in the study, named with their GenBank accession numbers. The exons are shown as black boxes. Numbers above exons refer to nucleotide positions in
DIO2 gene (NC_000014.8, region 80663869…80678525). Catalytically active DIO2 is translated from variant 1 or variant 2. Right panel: electrophoretic analysis of two DIO2
splicing variants. Numbers above gel refer to variant 1 (1) and variant 2 (2). C. Real-time PCR analysis of DIO2 mRNA expression in pituitary samples: non-tumorous pituitary
samples (n=9), non-functioning gonadotroph adenomas (NFPA-GO, n=20), non-functioning lactotroph adenomas (NFPA-PRO, n=1), non-functioning adenomas subtype
3 (NFPA-subtype 3, n=2), null-cell adenomas (NFPA-null cell, n=1), growth-hormone secreting adenomas (Acromegaly, n=3), and corticotropinomas (Cushing, n=1).
D. Validation of DIO2mRNA expression in HepG2 cells (n=1) and ﬁvematched pairs of papillary thyroid carcinoma (PTC-T, n=5) and control thyroid samples (PTC-N, n=5). Statistical
analysis was performed using t-test. *pb0.05, **pb0.01.
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variable and no statistically signiﬁcant differences were found between
control and tumor samples (Fig. 2). The control experiments performed
in thyroid tissue samples conﬁrmed that the expression of DIO2 was
decreased in PTC when compared with their matched–paired control
samples. In HepG2 cells no DIO2 expression was detected.
Real-time PCR analysis of DIO1 showed no ampliﬁcation signal
before the 40th cycle both in non-tumorous and tumorous pituitary
samples. It is generally acknowledged that Ct values exceeding 40 cycles
should not be trusted as informative [36]. However, it is also known that
quantitative analysis of rare transcripts in pools of total RNA can be difﬁ-
cult [37]. Therefore, in order to provide veriﬁcation of the analysis
performed on cDNA transcribed from total RNA isolated from pituitary
samples, we used a purchased pool of normal pituitary Poly A+ RNA.
This RNA is enriched for mRNA transcripts with two rounds of
oligo(dT)-cellulose puriﬁcation and was already used in a number of
studies [38–41]. Real-time PCR analysis performed on cDNA transcribed
from this RNA resulted inmean Ct values 38.21 (S.E.=0.404, n=3) (not
shown), thus on the border of trustable Ct values. In contrast, the expres-
sion of DIO1was detectable in thyroid and HepG2 samples. The expres-
sion of DIO1 was decreased in 3 of the 5 analyzed PTC samples when
compared to paired control tissues. These results are in agreement
with previously published studies [33–35].
Furthermore, to get an insight into DIO1 expression in normal
pituitary and other human tissues, we evaluated its expression using
BioGPS and data from high density oligonucleotide array study,
performed on 79 human tissues [42,43]. This analysis revealed that
the highest expression of DIO1 was found in the kidney, fetal liver,
fetal thyroid, as well as thyroid, and liver from an adult organism. In
contrast, the expression of DIO1 in the pituitary was much lower and
comparable to its expression in skeletal muscle, central nervous system
or skin (Supplementary Fig. 2S).Together, the results described above suggested that the expres-
sion of DIO1 in the studied pituitary samples was beyond sensitivity
of real-time PCR analysis.
3.3. Alterations in DIO1 sequence
To identify the mechanism underlying the variations in DIO1 tran-
scripts we analyzed the sequences of cloned variants in a search for
potential mutations or polymorphisms that could possibly affect
alternative splicing. The PCR products obtained on genomic DNA
extracted from the pituitary samples were sequenced to conﬁrm nucleo-
tide changes detected in transcripts. We found two SNPs, rs2235544
(15710C-A in NC00000_1.9) and rs11206244 (15841C-T in NC_000001.
9; also known as D1-C785T) (Table 1). Regarding rs2235544, 9 samples
were homozygous for C, 8 samples were homozygous for A, and 13
samples were heterozygous. The rs11206244 SNP was found as a homo-
zygous C in 12 samples, as homozygous T in 5 samples, and as heterozy-
gous C/T in 13 samples. There was no association between these SNPs
and the pattern of DIO1 splicing (Table 1). We found only one heterozy-
gous mutation causing C62T substitution (numbering according to
NC_000001.9), located in exon 1 of splicing variant 1 identiﬁed in tumor
sample 7 (Table 1). This mutation did not inﬂuence the amino acid
sequence of DIO1 since it changed codon CTC into CTT, which both code
for leucine. No other alterations in DIO1 DNA sequence were found.
3.4. The inﬂuence of splicing factor SF2/ASF on DIO1 splicing
Finally, we investigated the potential regulators of DIO1 alternative
splicing. Alternative splicing is regulated by a signiﬁcant number of pro-
teins, including splicing factors [14]. One of the so far best characterized
splicing factors is SF2/ASF, recently described as an oncoprotein
[15–18]. In our previous study performed on renal cancer we suggested
769A. Piekielko-Witkowska et al. / Biochimica et Biophysica Acta 1832 (2013) 763–772that SF2/ASF might be a regulator of DIO1 splicing [20], thus we
performed computational prediction of SF2/ASF binding sites in DIO1
sequence (Supplementary Table 1S). We found that the top scored
putative binding sites of SF2/ASF were located in exon 3 which
suggested that the observed inclusion or exclusion of exon 3 into
mature DIO1 transcript could possibly be regulated by SF2/ASF. More-
over, the putative predicted binding sites for SF2/ASF were conserved
in rat DIO1 sequence (Fig. 3). To investigate the possible regulation of
DIO1 splicing by SF2/ASF we performed siRNA-mediated silencing of
SF2/ASF in rat pituitary tumor GH3 cells and analyzed patterns of alter-
natively spliced DIO1 variants (Fig. 3). PCR performed on rat cells
revealed two DIO1 splice variants, homologous to human variant 1
(consisting of exons 1, 2, 3 and 4) and 4 (consisting of exons 1, 2,
and 4). Silencing of SF2/ASF resulted in a statistically signiﬁcant
(pb0.05) change of ratio between variant 1 and variant 4, increasing
the expression of variant 4, deprived of exon 3 (Fig. 3).
Electrophoretic analysis of PCR-derived DIO2 splice variants in
GH3 cells revealed only one band (902 bp), representing transcript
NM_031720.3, homologous to human DIO2 splice variant 1. Thus, in
contrast to DIO1, the splicing pattern of DIO2 was not affected by
silencing of SF2/ASF expression (Fig. 3).
Subsequently, a real-time PCR analysis of SF2/ASF expression was
performed on cDNAs derived from 28 tumor and 9 control samples.
The expression of SF2/ASF mRNA was statistically signiﬁcantly
(pb0.001) increased by 1.6-fold in pituitary adenomas when compared
with non-neoplastic pituitary samples (Fig. 3). The same statistically
signiﬁcant upregulation was observed in subgroups of non-functioning
adenomas (Supplementary Fig. 3S). To exclude the possibility that the
obtained results could be biased by contamination of adenoma speci-
mens with non-tumorous tissue, we excluded all non-functioningFig. 3. The effect of SF2/ASF silencing on DIO1 and DIO2 alternative splicing in GH3 cells. A.
sequence fragment containing putative binding motive for SF2/ASF. The motif predicted us
after siRNA-mediated silencing of SF2/ASF in GH3 cells. The representative gel scan shows PC
The schematic drawing of two splicing variants of DIO1 is shown in the middle with putative
var1:var4 ratio in GH3 cells transfected with siRNA against SF2/ASF (siSF2/ASF) or negative
were collected from densitometric analysis of electrophoretic gels from four independent ex
splicing after SF2/ASF silencing. B. Representative Western-blot showing decreased express
adenomas, n=9 for non-tumorous pituitary samples, n=28 for tumorous pituitary samplegonadotroph adenoma samples in which traces of Pit-1 and POMC
were detected. Statistical analysis performed in this subpool of NFPA
samples conﬁrmed that the expression of SF2/ASF was upregulated in
pituitary tumors in comparison with non-neoplastic pituitary samples
(Supplementary Fig. 3S).
4. Discussion
In this study we found signiﬁcant differences in the expression pat-
terns of DIO1 and DIO2 transcripts in pituitary adenomas. While most
tumor samples expressed multiple differently spliced DIO1 variants,
no DIO1 transcripts were detected in non-neoplastic pituitaries. In con-
trast, DIO2 was expressed both in adenomatous and non-neoplastic
pituitaries but only two different DIO2 transcripts were identiﬁed.
Moreover, we showed that alternative splicing of DIO1 is regulated by
oncoprotein SF2/ASF whose expression is increased in pituitary
adenomas.
DIO1 transcripts in pituitary adenomas were detectable using
RT-PCR but their expression was very low, beyond the sensitivity of
real-time PCR. We therefore used a two-round PCR reaction, which
is a procedure suggested for detection of extremely rare splicing
events [44]. This technique is signiﬁcantly more sensitive than stan-
dard real-time procedure involving only one round of a maximum
number of 40 PCR cycles. Thus, although a two-round PCR does not
allow for quantitative analysis, it is a perfect method for qualitative
analysis, and indeed, allowed us to detect rare DIO1 splice variants
in pituitary samples. These transcripts were composed of different
exonic combinations. The sequences of two variants were identical
to those identiﬁed previously in renal cancer tissue [20]. The expres-
sion of multiple DIO1 splice variants in pituitary adenomas raises theUpper panel: sequence alignment of rat (rDIO1) and human (hDIO1) type 1 deiodinase
ing SFmap tool is in gray box. Lower panel: changes in ratios of rDIO1 splicing variants
R products corresponding to variant 1 (var1) and variant 4 (var4) DIO1 splice variants.
ESEs binding SF2/ASF located in exon 3 shown by an arrow. The plot shows changes of
control (siNeg). Statistical analysis was performed using t-test. ****pb0.0001. The data
periments. Below similar analysis performed for rDIO2 shows no changes in alternative
ion of SF2/ASF after siRNA transfections. C. Upregulation of SF2/ASF mRNA in pituitary
s. Statistical analysis was performed using t-test. ***pb0.001.
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reveal that apart from variants 1 and 4 all DIO1 splice variants lack
nucleotides encoding catalytically active center (not shown) and there-
fore the putative proteins coded by these transcripts would be inactive.
Moreover, very low expression of DIO1 mRNAs suggests that even if
translated, the protein levels would rather not inﬂuence intrapituitary
thyroid hormone concentrations.
Our results are to some extent in agreement with previously pub-
lished studies. Tannahill et al. showed that DIO1 activity was not
detectable in most of the analyzed pituitary samples, regardless of
their tumorous or non-tumorous status [24]. Moreover, in the major-
ity of pituitary tissues analyzed in that study, DIO1 mRNA expression
was at the border or even beyond of detection limits. In our study,
even though a pre-puriﬁed RNA mixture of normal pituitary samples,
enriched in mRNA was used as a template in real-time PCR reaction,
the expression of DIO1 mRNA was still at the border of real-time
PCR sensitivity, conﬁrming the results of Tannahill et al. [24]. In con-
trast, in a study by Baur et al., who did not analyze mRNA expression,
DIO1 activity was detectable in all the three normal pituitaries ana-
lyzed; however, it was undetected in 15 out of 43 analyzed adenoma-
tous pituitary samples [23]. Moreover, in most cases the activity of
DIO1 was lower than the activity of DIO2. The reasons for discrepan-
cies in results of these studies are not known. The possible explana-
tion could involve different drug treatments before the material was
collected. Unfortunately, in our study we were not able to obtain
the information on patient treatment, nor was it provided in the
study of Tannahill et al. Interestingly, high density oligonucleotide
array study, performed on 79 human tissues [42,43] reveals that the
expression of DIO1 in pituitary gland is very low (Supplementary
Fig. 2S), and comparable to its expression in skeletal muscle, central
nervous system or skin that are tissues recognized as expressing
mainly DIO2 [45]. These results conﬁrm our analysis showing low
DIO1 expression in the pituitary and strongly suggest that DIO1 is
indeed not the major enzyme involved in 5′ deiodination in this gland.
Five of nine identiﬁed DIO1 splice variants were devoid of exon 3.
Computational analysis revealed that this exon contains themost highly
ranked putative binding sites (ESEs) of splicing factor SF2/ASF. Silencing
of this splicing factor in pituitary tumor GH3 cells shifted the ratio of
transcript variants 1 and 4. Since splicing variant 4 is devoid of exon 3,
this indicates that SF2/ASF regulates inclusion of exon 3 in DIO1 tran-
script. Interestingly, it was previously shown that SF2/ASF is involved
in the regulation of alternative splicing of pituitary transcripts. Solis et
al. found that alternative splicing of growth hormone is regulated by
two antagonistically acting splicing factors, SF2/ASF and SC35 [46].
Binding of SF2/ASF to ESE located in exon 3 activates inclusion of exon
3 into the growth hormone primary transcript. In our study silencing
of SF2/ASF resulted in enhanced exclusion of exon 3 from DIO1 mRNA
suggesting the mechanism similar to that inﬂuencing alternative
splicing of growth hormone. The increased expression of SF2/ASF
in pituitary adenomas may suggest that in adenomatous tissues DIO1
transcripts including exon 3 could be preferentially expressed. Indeed,
splice variants with exon 3 were the most abundant and were
expressed in 14 of 19 samples in which DIO1 transcripts were detected.
However, the presence of transcripts lacking exon 3 in 9 tumor speci-
mens suggests that apart from SF2/ASF, other factors might inﬂuence
alternative splicing of DIO1. This is supported by the in silico analysis
of DIO1 sequence using SFmap software which predicts binding sites
for multiple other splicing factors including SRp20 and MBNL (not
shown). Interestingly, the putative binding sites for these two splicing
factors are affected by C/T polymorphism rs11206244 and in the pres-
ence of T allele bindingmotifs for both splicing factors are lost. Our anal-
ysis did not show association of any of these SNPs with splicing pattern
of DIO1. Therefore, whether SRp20 and MBNL are indeed regulators of
DIO1 splicing remains to be established by future studies. Another
mechanism contributing to posttranscriptional regulation of DIO1
could be nonsense-mediated mRNA decay (NMD). In two of the splicevariants identiﬁed in our study (JK990801 and JK990798 in Fig. 1) pre-
mature termination codons (PTCs) are located more than 50 nucleo-
tides upstream from the ﬁnal exon–exon junction and therefore they
are potential candidates for degradation by NMD mechanism. This is
in agreement with our previous ﬁndings regarding DIO1 splice variants
cloned from renal cancer [20]. Since our results revealed very low
expression of DIO1 mRNA in the pituitary, the SF2/ASF-mediated
regulation of its alternative splicing is most probably of no importance
for the physiology of pituitary cells. Nevertheless, this regulatory
mechanism can be potentially important for the physiology of DIO1-
expressing tissues, for instance the thyroid. The expression of SF2/ASF
was reported to be increased in thyroid cancer [15] what may suggest
its potential effects on deregulation of DIO1 alternative splicing.
We found only one DNA-encoded mutation (C62T) in exon 1
which did not affect any splicing motifs, nor the amino acid sequence
of DIO1 protein. This is in line with the fact that no mutations in
deiodinases encoding genes were reported so far in different pathol-
ogies [8,47].
In comparison with DIO1, alternative splicing of DIO2 was surpris-
ingly stable. We found only two DIO2 splicing variants expressed in
both pituitary adenomas and non-tumorous pituitary samples. This is
in agreement with previous study of Tannahill et al. [24] who observed
DIO2 mRNA expression in normal pituitaries and in pituitary tumors.
The two identiﬁed DIO2 splice variants differ in their 5′ untranslated
regions (5′UTRs). As shown byGereben et al., the structure of 5′UTR sig-
niﬁcantly inﬂuences the expression of DIO2 protein [48]. According to
their studies, long 5′UTR, consisting of more than 600 nucleotides,
reduced DIO2 translation efﬁciency by approximately 5-fold when test-
ed in a reporter construct containing chickenDIO2 cDNA. Shorter 5′UTR
variant, encoded by nucleotides 41–244 of humanDIO2 gene (construct
named hdio2–5′UT(41/240)-cD2 in [48]) yielded inmore than two-fold
higher deiodinase activity. Two DIO2 splice variants identiﬁed in our
study code for exactly the same protein and differ only in the length
of their 5′UTRs which may suggest that potential changes in their rela-
tive expressions may inﬂuence the level of DIO2 protein.
The expression of DIO2mRNAs was decreased in growth hormone
secreting adenomas when compared with non-tumorous samples.
This result is in agreement with a recent study on MEN1-associated
pituitary adenoma showing that DIO2 expression was decreased in
mammosomatotroph tumor [38]. In residual types of adenomas
DIO2 expression was variable and no statistically signiﬁcant differ-
ences were found between tumor and control samples. These results
are similar to those obtained by Baur et al. [23] who reported that rel-
ative activities of DIO2 varied in samples derived from different types
of tumors and even in normal tissues. In contrast, Tannahill et al. [24]
showed upregulation of DIO2 mRNA in pituitary adenomas when
compared with non-tumorous controls. One of the possible reasons
for discrepancies in results of these studies could be the fact that in
the study of Tannahill et al. much more tumor samples (102) were
analyzed when compared to our study or to study of Baur et al. [23].
The signiﬁcance of our ﬁndings is strictly related to the importance
of deiodination for physiology of the pituitary gland. It is generally
acknowledged that DIO2 provides locally synthesized T3, a hormone
which inﬂuences the key physiological processes in the pituitary,
including its development, cellular proliferation [6,7] as well as secretion
of hormones: TSH, PRL, and GH [3–5]. It was suggested that depending
on the cell context, T3 may stimulate apoptosis [49] or proliferation of
pituitary cells [50,51]. The role of DIO1 is currently amatter of discussion.
Although DIO1 was initially identiﬁed as a T3-synthesizing enzyme, it is
currently known that its substrate afﬁnity is higher for reverse T3 (rT3)
than for T4 [47]. Interestingly, it was shown that rT3 and the product of
its deiodination, 3,3′-T2, stimulate the production of growth hormone
and consumption of glucose in rat pituitary cells. However, obtaining
these effects required the use of signiﬁcantly higher concentrations of
these hormones when compared to sufﬁcient concentrations of T3 [52].
Moreover, in contrast to the effects of disruption of DIO2, knockout of
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may suggest that the expression of DIO2, a crucial regulator of the pitui-
tary physiology, is protected against posttranscriptional deregulation
during pituitary tumoral transformation. In contrast,DIO1whose activity
is not essential for the pituitary, may be more prone to disturbances of
alternative splicing.
To our knowledge our study is the ﬁrst showing increased expression
of SF2/ASF splicing factor in pituitary adenoma. SF2/ASF is encoded by a
proto-oncogene [15] and it is possible that its upregulationmayhave con-
sequences on the pituitary tumorigenesis. SF2/ASF promotes non-small
cell lung cancer survival by enhancing survivin expression [18]. The
expression of survivin in pituitary tumors is increased [56,57], therefore
it would be interesting to investigate whether this upregulation is linked
with enhanced expression of SF2/ASF. Moreover, SF2/ASF-induced
changes in alternative splicing affect several key genes and pathways
involved in tumoral transformation (e.g. Ras-MAPK and PI3K-mTOR)
[15] or apoptosis regulation (e.g. BIN1, BIM, BCLX (BCL2L1), MCL1, and
CASP2 and CASP9) [16,58]. Interestingly, induced downregulation of
SF2/ASF reverses tumoral transformation suggesting that SF2/ASF-coding
gene might be a possible target for therapeutic interventions [15]. There-
fore, the potential role of SF2/ASF in pituitary tumorigenesis needs further
investigation.
In conclusion, we demonstrate that the patterns of expression and
alternative splicing ofDIO1 andDIO2 are different in pituitary adenomas
and provide the new mechanism of posttranscriptional regulation of
DIO1 by oncogenic splicing factor SF2/ASF. This latter ﬁnding comple-
mentsmicroRNA-dependent regulation ofDIO1 showed in our previous
study [59]. Increased expression of SF2/ASF in pituitary tumors suggests
that its effects on tumor-related deregulation of transcripts in pituitary
adenomas may be signiﬁcantly broader, which requires further
investigation.
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